Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have shown significant efficacy in patients with brain metastases (BMs) from EGFR‐mutated non‐small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and lung cancer.